By Denny Jacob AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival.

More than 50,000 Australians have Tourette syndrome. A new report has highlighted the ongoing barriers those with the condition and other tic disorders face.

NEED TO KNOW The two-time NBA MVP told CNBC’s Alex Sherman he “still” struggles with impostor syndrome In March, Steph Curry became the first NBA player to reach 4,000 career 3-pointers ...